Decitabine

Cytostatic · Antimetabolite

Indications

Treatment of newly diagnosed acute myeloid leukaemia in patients over 65 yrs of age who are not candidates for standard induction chemotherapy.

Dosage

Adults and Elderly: IV: 3-Day Regimen: Administer at a dose of 15 mg/m2 by continuous IV inf over 3 hrs repeated every 8 hrs for 3 days. Repeat cycle every 6 wks upon haematologic recovery (ANC at least 1,000/µL and platelets at least 50,000/µL) for a minimum of 4 cycles. A complete or partial response may take longer than 4 cycles. Delay and reduce dose for hematologic toxicity. See literature for dose modifications due to toxicity. 5-Day Regimen: Administer at a dose of 20 mg/m2 by continuous IV inf over 1 hr repeated daily for 5 days. Delay and reduce dose for hematologic toxicity. Repeat cycle every 4 weeks upon hematologic recovery (ANC at least 1,000/µL and platelets at least 50,000/µL) for a minimum of 4 cycles. A complete or partial response may take longer than 4 cycles. See literature for dose modifications due to toxicity.

Administration

Administered via IV infusion. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if there is evidence of particulate matter or discoloration. Premedication with antiemetics is recommended. Reconstitution: Aseptically reconstitute Decitabine with room temp (20-25°C) 10 mL of Sterile Water for Injection. Upon reconstitution, the final conc of the reconst Decitabine soln is 5 mg/mL. Must dilute the reconst solution with 0.9% NaCl Inj or 5% Dextrose Inj prior to administration. Temp of the diluent (0.9% NaCl Inj or 5% Dextrose Inj) depends on time of adm after preparation. For Administration Within 15 Minutes of Preparation: If Decitabine is intended to be adm within 15 mins from the time of prep, dilute the reconst soln with room temp (20-25°C) 0.9% NaCl Inj or 5%…

Adverse Effects

Neutropaenia, thrombocytopaenia, anaemia and pyrexia.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Precautions: Perform complete blood counts and platelet counts before starting treatment. HBV screening with HBsAg, anti-HBc, total Ig or IgG, and antibody to anti-HBs prior to beginning or at the beginning of systemic anti-cancer therapy; do not delay treatment for screening/results.

Advice to Patient

Men and women of reproductive potential must use effective contraception before starting treatment and for 6 months after stopping treatment. Due to risk of myelosuppression, patients must report any symptoms of infection, anaemia, or bleeding to their healthcare provider.

Pharmacokinetics

Metabolism: Possibly via deamination by cytidine deaminase. Half-life elimination: Approx. 0.5-0.6 hrs.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.